444 results
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
3 Jan 24
Regulation FD Disclosure
5:00pm
There is no assurance that any of these measures will actually be implemented 2 Assuming favorable results from this study
Development Candidate DPI
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
21 Dec 23
Termination of a Material Definitive Agreement
12:31pm
operations and satisfy the Company’s liabilities and obligations in a timely manner. There can be no assurance that this will be the case. Also
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
28 Nov 23
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
4:41pm
be no assurance that this will be the case. Also, such statements assume that there are no significant unexpected developments or events that delay
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
14 Nov 23
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
3:57pm
release, continue the Company’s operations and satisfy the Company’s liabilities and obligations in a timely manner. There can be no assurance
8-K
aupmi hka8kqyfl6o
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
8-K
88ev56v
17 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:37pm
8-K
pjtf1gso3 05228nq
10 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:01am
8-K
EX-99.1
ye9iv521ql
8 Sep 23
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
4:50pm
NT 10-Q
8zwxf8k4718axpso
14 Aug 23
Notice of late quarterly filing
4:38pm
8-K
EX-10.1
a47gxvy3jo
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
18uvkhmc2lm3ks b0kl
3 Aug 23
Prospectus supplement with pricing info
4:55pm
FWP
u4lkk5wtkgig
27 Jul 23
Free writing prospectus
6:08am